喹硫平合并石杉碱甲治疗阿尔茨海默病伴明显精神病性症状的疗效和安全性

摘要

Objective:To study the efficacy and safety of Quetiapine combined with Huperzine A in treatment of Alzheimer dis-ease. Methods:60 Alzheimer inpatients in our hospital who conform to the Chinese classification and Diagnostic criteria of mental dis-eases-3rd edition undergone the treatment of Quetiapine combined with Huperzine A for 12 weeks. Before and 2, 4 and 8 weeks after the treatment, the efficacy was evaluated by positive and negative symptom scale (PANSS), and the adverse reactions were evaluated by treatment emergent symptom scale (TESS). Before and 12 weeks after the treatment, cognitive functions was evaluated by Mini-mental state examination. Results: The PANSS score reduced significantly 8 weeks after the treatment, The MMSE score reduced sig-nificantly 12 weeks after the treatment and less adverse reactions occurred. Conclusions: Quetiapine combined with Huperzine A in the treatment of Alzheimer disease is a safe and effective treatment with less adverse reactions and more tolerability.%目的：：探讨喹硫平合并石杉碱甲治疗阿尔茨海默病的疗效和安全性。方法：60例在我院住院治疗的阿尔茨海默病患者，符合中国精神障碍分类与诊断标准第3版诊断标准。患者接受为期12周的喹硫平合并石杉碱甲的治疗，在治疗前及治疗2、4、8周采用阳性与阴性症状量表(PANSS)评定疗效，采用治疗中出现的症状量表(TESS)评定不良反应。于治疗前及治疗12周采用简易智力状态量表(MMSE)评定认知功能。结果：治疗8周时 PANSS 评分显著降低，治疗12周 MMSE 评分显著降低，不良反应较少。结论：喹硫平合并石杉碱甲治疗阿尔茨海默病安全有效，不良反应少，耐受性较好。